$150.15 Million Venture Structured Investment In Patho Care

Leading health technology investment firm Hamershlag Private Capital Management Limited (HPCM) has announced a significant venture investment in Patho Care, a leader in the “lab on a chip” non-invasive point-of-care diagnostic tests. Patho Care’s Raman spectroscopy-based testing platform is supported by 17 patents.

The deal, valued at $150.15 million, was structured as an acquisition and recapitalization using newly issued common stock and cash through a newly formed entity, PathoCare Holdings, to streamline the investment and operational framework.

This strategic funding reflects HPCM’s commitment to advancing innovative healthcare solutions while generating substantial returns for its investors. And the deal terms were set up to ensure Patho Care has the resources to expand its operations and establish its market position.

This investment also facilitated the repayment of existing financial obligations held by Patho Care. As of December 18, 2022, a critical deal component included settling PathoCare’s outstanding notes and ensuring the company’s financial readiness to embark on this next growth phase.

This investment will empower Patho Care, LLC to broaden its service offerings, enhance operational efficiencies, and innovate in key areas of diagnostics testing. And the collaboration between HPCM and PathoCare Holdings is set to unlock new growth opportunities while maintaining the company’s legacy of emerging technology.

This venture marks a major milestone in Hamershlag Private Capital Management Limited’s investment portfolio, reinforcing its reputation as a trusted partner for companies seeking strategic growth capital. And these parties are dedicated to ensuring a seamless transition and maintaining the highest service levels for PathoCare’s stakeholders.

KEY QUOTES:

“Patho Care, LLC is a distinguished leader in healthcare diagnostics through the utilization of a novel approach with spectroscopy and this investment aligns with HPCM’s strategy of partnering with high-potential companies in dynamic industries. Our commitment to delivering transformative value through innovative investments underscores our confidence in PathoCare’s vision and capabilities.”